实体器官移植后免疫抑制患者的局限性肾癌结局
本研究比较了实体器官移植后因免疫抑制治疗的局限性肾细胞癌患者与匹配的非移植患者的结局。81例移植患者(手术65%、消融23%、监测11%)的生存结局与匹配非移植队列相当。
要点
- 移植后免疫抑制的局限性肾癌患者手术结局与非移植患者相当。
- 主动监测在移植患者中未增加治疗、转移或死亡风险。
核心结论
- 在所有管理策略中,实体器官移植后非转移性肾细胞癌患者尽管长期免疫抑制,结局与非移植患者无差异。
- 应进一步研究主动监测在该人群中的作用。
研究设计与样本
- 回顾性匹配队列研究,移植患者来自实体器官移植数据库,2000-2020年移植后组织学诊断非转移性肾细胞癌。
- 81例移植患者(手术65%、消融23%、监测11%)按治疗类型、年龄、肿瘤大小和分级(若有)与非移植患者匹配。
主要发现
- 主动监测队列长期随访显示,治疗概率、转移进展或生存无差异;移植与全因死亡风险无关(HR 0.52,P=0.5)。
临床怎么用
- 移植后免疫抑制的局限性肾癌患者可按非移植患者的标准策略进行手术、消融或主动监测。
- 主动监测可作为该人群的合理选择,尤其适合手术风险高的患者。
局限性
- 回顾性设计,样本量有限(81例移植患者)。
- 部分匹配因素(如分级)仅在可获得时使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes of patients with localized renal cell carcinoma (RCC) receiving immunosuppressive therapy due to prior organ transplant to a matched cohort of nontransplant patients. METHODS: Patients were identified from a solid organ transplant database with tissue diagnosis of nonmetastatic RCC after transplantation between 2000-2020. Transplant patients were matched to nontransplant patients with nonmetastatic RCC based on treatment type, age, tumor size, and grade if available. Clinical variables and survival outcomes were compared. RESULTS: Among 81 transplant patients with nonmetastatic RCC (surgery 65%, ablation 23%, surveillance 11%), survival outcomes were comparable to matched nontransplant cohorts. In the surgical cohort, metastasis-free survival and overall survival did not differ between transplant and nontransplant patients, and multivariable analysis confirmed transplant status was not associated with increased risk of metastasis (HR 0.94, P = .9) or mortality (HR 1.58, P = .2). In the ablation cohort, transplant patients had better local recurrence-free survival (log-rank P = .01) compared to nontransplant patients. No difference was identified in metastasis-free or overall survival with regards to transplant status (HR 4.75, P = .2; HR 0.98, P = .9). Among patients managed with active surveillance, long-term follow-up demonstrated no differences in probability of treatment, metastatic progression, or survival, and transplantation was not associated with increased risk of death from any cause (HR 0.52, P = .5). CONCLUSION: Across all management strategies, no difference was identified in outcomes for patients with nonmetastatic RCC after solid organ transplantation compared to nontransplant patients, despite chronic immunosuppression. Further studies should evaluate the role of active surveillance in this population.
引用
- Shah PV, Abel EJ, Mezrich JD, et al. Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ Transplantation. Urology. 2025. PMID: 41389849. doi:10.1016/j.urology.2025.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。